Voxeldance Strengthens Executive Team with Key Hire
25.5.2021 08:12:00 EEST | Business Wire | Press release
Voxeldance, a leading provider of digital manufacturing software for additive 3D printing, today announced the appointment of Robert Yusin as Chief Operating Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005861/en/
Voxeldance appoints Robert Yusin as Chief Operating Officer (Photo: Business Wire)
Yusin will lead operations and collaborate with the executive team to drive global growth. He brings more than 25 years of global experience in manufacturing applications, security, network, storage, and cloud in software and hardware. He was formerly one of three founders at Oqton. He also served as Director of Sales/business development at Autodesk where he pioneered the Asia market for the Autodesk Consumer Group (ACG) division. His previous experience includes executive roles at Accelops (Fortinet), Trustwave, Symantec, Loglogic (TIBCO), McAfee, and StorageTek. Yusin has built and managed companies and functions from zero to $300+ million in revenue.
“Robert brings a tremendous record of success and I am excited to add him to the company’s executive team,” said Zhang Chaoxin, CEO of Voxeldance. “His experience with startups with successful exits and domain expertise in manufacturing will help Voxeldance expand operations to support the next phase of growth.”
“Voxeldance offers software solutions that will integrate with the end-to-end digital factory for customers and partners,” said Robert Yusin. “The leadership team has built a great company as evidenced by the portfolio of large enterprise customers and partners; I look forward to contributing to the team.”
Additional Resources:
Official website: https://www.voxeldance.com
Video site: https://www.youtube.com/channel/UC1d6KPoLhTjwREMPRuG2MFg?view_as=subscriber
Twitter: https://twitter.com/VoxelDance
Facebook: https://www.facebook.com/VoxelDance-666723630455229/
WeChat Public Number: VoxelDance
LinkedIn: http://www.linkedin.com/company/Voxeldance
Customer case studies and evaluations: https://voxeldance.com/blog
Sales inquiry: info@voxeldance.com
About Voxeldance:
Voxeldance is the recognized leader for manufacturing software solutions for additive 3D printing, with a high adoption rate in use with hardware technology partners and service bureaus that integrate Voxeldance flagship additive software with their solutions. Voxeldance products are secure, cost effective and are easily adaptable to integrate with existing technology for the digital factory. The software products are built on technology advancements that will proactively accelerate workflow processes allowing the operator to effectively streamline hours of time for operational improvements in supporting many vertical use cases. Voxeldance is headquartered in Shanghai China and can be found online at http://www.voxeldance.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005861/en/
Contact information
Media Contact:
Voxeldance Media Relations, media@voxeldance.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom